What is Prosetta Biosciences?
Prosetta Biosciences is a San Francisco-based biotechnology enterprise dedicated to the development of novel therapeutics. The company distinguishes itself through a specialized focus on the assembly of multi-protein complexes within cells. By identifying small molecules that modulate these complex biological interactions, Prosetta aims to restore molecular homeostasis, offering a transformative strategy for treating complex diseases. Their research-driven model serves as a critical bridge for healthcare professionals and drug discovery researchers seeking to address unmet medical needs through precision-engineered biological interventions.
How much funding has Prosetta Biosciences raised?
Prosetta Biosciences has raised a total of $46.3M across 5 funding rounds:
Series A
$8M
Series B
$5M
Series C
$2M
Series D
$31.1M
Debt
$150K
Series A (2007): $8M, investors not publicly disclosed
Series B (2008): $5M, investors not publicly disclosed
Series C (2012): $2M, investors not publicly disclosed
Series D (2015): $31.1M featuring Alger and Takeda Pharmaceutical
Debt (2021): $150K backed by PPP
Key Investors in Prosetta Biosciences
Takeda Pharmaceutical
A global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, focusing on gastroenterology, oncology, neuroscience, and rare diseases.
Alger
An independent investment management firm established in 1964, specializing in growth equity strategies and long-term asset management.
PPP
Public-Private Partnership
What's next for Prosetta Biosciences?
With the recent infusion of $150K, Prosetta Biosciences is well-positioned to accelerate its R&D initiatives and expand its therapeutic portfolio. The company is expected to prioritize the clinical validation of its lead candidates, leveraging its unique platform to address high-priority disease areas. As the firm transitions into its next phase of growth, the focus will likely shift toward strategic partnerships and the scaling of its proprietary technology to meet the rigorous demands of the global pharmaceutical market. This capital deployment will be instrumental in maintaining the company's competitive edge in the rapidly evolving landscape of molecular medicine.
See full Prosetta Biosciences company page
